Table 3.
Final results of mixed models examining baseline predictors of outcomes. Only variables associated with the outcome at a p-value of ≤0.10 are listed here. For the full model, see Supplementary Table 2. BMI, body mass index; CSF, cerebrospinal fluid; ESS, Epworth Sleepiness Scale; PIGD, postural instability gait disorder; MoCA, Montreal Cognitive Assessment; RBDSQ, REM Sleep Behavior Disorder Questionnaire; SBR, specific binding ratio; SCOPA-AUT, Scales for Outcomes in Parkinsons—Autonomic; SBP, systolic blood pressure
| Outcome | Predictor (All baseline values)i | Multivariate Effect Estimate | Multivariate | Multivariate |
| β (95% CI) | p-value | Adjusted R2 | ||
| MDS-UPDRS Total Score Off - Change from Baseline | Disease duration | 0.1596 (0.0204, 0.2988) | 0.0246 | |
| N = 373 | MDS-UPDRS total score in OFF | –0.1345 (–0.2097, –0.0593) | 0.0005 | 0.1383 |
| Gender (Male) | 1.9042 (0.0550, 3.7535) | 0.0436 | ||
| CSF amyloid-β1–42 | –0.0031 (–0.0058, –0.0005) | 0.0217 | ||
| Mean striatum SBR | –2.5317 (–4.8456, –0.2179) | 0.0320 | ||
| SBP | –0.0779 (–0.1468, –0.0090) | 0.0267 | ||
| SCOPA-AUT | 0.1413 (–0.0174, 0.3000) | 0.0809 | ||
| MDS-UPDRS Total Score ON - Change from Baseline | MDS-UPDRS total score in ON | –0.1990 (–0.2721, –0.1260) | <0.0001 | |
| N = 374 | CSF amyloid-β1–42 | –0.0028 (–0.0054, –0.0001) | 0.0407 | 0.0533 |
| Gender (Male) | 1.6797 (–0.1650, 3.5244) | 0.0743 | ||
| MoCA | –0.3482 (–0.7439, 0.0474) | 0.0844 | ||
| SCOPA-AUT | 0.1487 (–0.0105, 0.3079) | 0.0671 | ||
| MDS-UPDRS Part III Score Off - Change from Baseline | Disease duration | 0.1377 (0.0405, 0.2349) | 0.0055 | |
| N = 382 | MDS-UPDRS part III score OFF | –0.1849 (–0.2567, –0.1131) | <0.0001 | 0.1156 |
| Clinical Site (US) | 1.1952 (0.2462, 3.5841) | 0.0246 | ||
| CSF amyloid-β1–42 | –0.0021 (–0.0039, –0.0002) | 0.0284 | ||
| Mean striatum SBR | –1.6005 (–3.1793, –0.0218) | 0.0469 | ||
| MDS-UPDRS Part III Score On - Change from Baseline | Disease duration | 0.1239 (0.0252, 0.2227) | 0.0140 | |
| N = 385 | MDS-UPDRS part III score ON | –0.2497 (–0.3199, –0.1795) | <0.0001 | 0.0345 |
| Clinical Site (US) | 1.9541 (0.3446, 3.5636) | 0.0174 | ||
| ESS | –0.1572 (–0.3351, 0.0207) | 0.0833 | ||
| CSF amyloid-β1–42 | –0.0019 (–0.0038, –0.0001) | 0.0417 | ||
| Mean putamen SBR - % Change from Baseline | CSF amyloid-β1–42 | 0.0055 (–0.0001, 0.0111) | 0.0526 | 0.2870 |
| N = 352 | Mean putamen SBR | –17.1848 (–23.6240, –10.7457) | <0.0001 | |
| RBDSQ | –1.0837 (–1.7730, –0.3945) | 0.0021 | ||
| Mean striatum SBR - % Change from Baseline | CSF amyloid-β1–42 | 0.0039 (–0.0003, 0.0081) | 0.0708 | |
| N = 351 | Mean striatum SBR | –6.2020 (–9.7532, –2.6508) | 0.0007 | 0.3563 |
| Modified Schwab &England (S&E) | 0.2417 (0.0037, 0.4797) | 0.0466 | ||
| RBDSQ | –1.0030 (–1.5268, –0.4793) | 0.0002 |
iAge, gender, disease duration, and the baseline value of the outcome were forced into each model.